The long term objectives of this application are to use the transgenic mouse as a model to elucidate the pathogenetic mechanisms responsible for the development of tissue injury and primary hepatocellular carcinoma (PHC) in chronic, human hepatitis B virus (HBV) infection.
The specific aims are to determine how closely this model resembles the chronic HBV carrier state in man and to establish the parameters necessary to induce tissue injury and PHC in these animals. HBV transgenic mice have been, and will be, produced by microinjection of unicellular embryos with cloned subgenomic fragments of HBV. Transgenic mice will be selected for pathogenesis studies based on gene expression and host-viral DNA integration sites using radioimmunoassay, immunofluorescence, immunoelectromicroscopy, Northern blotting, Southern blotting as well as cloning and sequencing techniques. Appropriate animals will be analyzed and manipulated immunologically to induce a potentially cytolytic immune response in vivo resulting in tissue injury. Direct and immunologically mediated tissue injury will be monitored by conventional pathologic analysis and animals will be monitored histologically for the development of tumors. The pathogenetic mechanisms responsible for the resultant disease will be analyzed in vitro by appropriate immunologic techniques including assessment of antigen specific helper, suppressor and cytotoxic T cell function, organ transplantation and adoptive transfer experiments as well as analysis of host-viral integration site and the structural organization of the integrated viral DNA sequences. This model provides a unique opportunity to perform experiments that are directly pertinent to the pathology and pathogenesis of the hepatitis B carrier state but are otherwise not possible.
| Wieland, Stefan F (2015) The chimpanzee model for hepatitis B virus infection. Cold Spring Harb Perspect Med 5: |
| Guidotti, Luca G; Isogawa, Masanori; Chisari, Francis V (2015) Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol 36:61-6 |
| Sitia, Giovanni; Iannacone, Matteo; Aiolfi, Roberto et al. (2011) Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog 7:e1002061 |
| Bissig, Karl-Dimiter; Wieland, Stefan F; Tran, Phu et al. (2010) Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 120:924-30 |
| Chisari, F V; Isogawa, M; Wieland, S F (2010) Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 58:258-66 |
| Yang, Priscilla L; Althage, Alana; Chung, Josan et al. (2010) Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 107:798-802 |
| Bandi, Prasanthi; Garcia, Mayra L; Booth, Carmen J et al. (2010) Bortezomib inhibits hepatitis B virus replication in transgenic mice. Antimicrob Agents Chemother 54:749-56 |
| Iannacone, Matteo; Sitia, Giovanni; Isogawa, Masanori et al. (2008) Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A 105:629-34 |
| Robek, Michael D; Garcia, Mayra L; Boyd, Bryan S et al. (2007) Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. J Virol 81:483-91 |
| Maier, Holly; Isogawa, Masanori; Freeman, Gordon J et al. (2007) PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 178:2714-20 |
Showing the most recent 10 out of 79 publications
